NEW YORK (GenomeWeb News) – Cenix Bioscience said today that it has expanded an oncology drug research agreement with AstraZeneca to include RNAi-based studies for respiratory and inflammation-related conditions.
Under the new agreement, which expands upon a deal announced in March, Cenix will complete at least three projects using its RNAi gene silencing technology as well as image analysis using Definiens’ Cellenger platform.
These studies will involve multi-pass genome-scale screens using assays developed by AstraZeneca in high-throughput RNAi studies in 384-well and 1,536-well formats.
Financial terms of the expanded agreement were not released.